Tanvex BioPharma, Inc. (TPE:6541)

Taiwan · Delayed Price · Currency is TWD

41.90

+0.60 (1.45%)

Apr 2, 2026, 1:30 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biotechnology (Startups)		61.41M	22.40M	5.41M	300.00K
Biotechnology (Startups) Growth		174.11%	314.43%	1702.00%	-
Total		61.41M	22.40M	5.41M	300.00K
Total Growth		174.11%	314.43%	1702.00%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan		53.70M	22.40M	5.41M	300.00K
Taiwan Growth		139.70%	314.43%	1702.00%	-
United States		7.71M	-	-	-
Total		61.41M	22.40M	5.41M	300.00K
Total Growth		174.11%	314.43%	1702.00%	-

Source: S&P Global Market Intelligence.